Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Critical Therapeutics
Age
12–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Male or female 12-70 years of age (inclusive).
2. Diagnosis of asthma for at least 6 months.
3. Morning FEV1 of 40-80% normal.
4. Demonstrated reversible airflow restriction.
5. Non-smokers.
6. On moderate doses of ICS with inadequate asthma control.
7. Signed ICF
You may not be if
1. Diagnosis of COPD.
2. Uncontrolled systemic illness.
3. Hypersensitivity to any component of ZYFLO CR
4. Any patient with an unscheduled visit to an ER or hospital for asthma exacerbation within past 3 months.
5. History of hepatitis or active liver disease.
6. ALT greater than 3xULN.
7. History of HIV infection
8. Recent history of drug or alcohol abuse.
9. Oral corticosteroids within one month, cromolyn sodium or nedocromil within 14 days, theophylline, LABA, ZYFLO, or leukotriene modifiers, warfarin or propranolol, inhaled anti-cholinergics, or combination LABA/ICS.
10. Omalizumab within 3 months.
11. Pregnant female.
12. Participation with 30 days in investigational study.
Clareo Health | Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS
